Cancer drug developer Antisoma plc (London Stock Exchange: ASM) today announces the launch of its Level One American Depositary Receipt (ADR) Program. This will enable US investors in Antisoma to trade in a dollar-denominated security and is intended as a step towards a full listing of Antisoma’s shares on NASDAQ.
